Compare Okta, Inc. (OKTA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Sana Biotechnology Inc — how do they compare? Okta, Inc. trades at $232.13 (market cap $38.50B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Okta, Inc. is far larger — about 46× Sana Biotechnology Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Sana Biotechnology Inc for 23 Days on average.
| OKTA | SANA | |
|---|---|---|
Market Cap | $38.50B | $836.71M |
Volume | 2,479,621 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $220.21 | $5.92 |
52-Week Low | $62.93 | $2.68 |
Typical Hold Time | 44 Days | 23 Days |
Enterprise Value | $36.25B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages and strong analyst support (73.58% buy ratings). The company reported a net income of $28 million in 2025, marking a return to profitability after losses in prior years, with revenue growing to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
The outlook is positive due to earnings beats, AI-driven growth potential, and improving cash flow, but risks include high valuation multiples (P/E of 132.66) and competitive pressures in cybersecurity. The stock trades above the consensus price target of $201.30, suggesting near-term consolidation may occur despite long-term growth prospects.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
